Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

ALK-Abello debuts its birch pollen allergy therapy in Germany

Key market for the new product

Novartis building

Novartis expands its generics franchise with natalizumab biosimilar

Says affordability is a challenge to access

- PMLiVE

TMC’s full data for inclisiran impresses at ESC

Marketing applications expected before end of year

- PMLiVE

Medimmune-born Viela files $150m IPO, eyes first product launch

Funds will help to push a number of pipeline candidates

- PMLiVE

Ardelyx gets second kidney disease trial win for tenapanor

Drug hit primary and all secondary endpoints

- PMLiVE

AZ unveils phase 3 Brilinta data in CAD and type 2 diabetes

Reduces CV events but falls down on increased bleeding risk

Roche Basel Switzerland

Roche’s flu drug Xofluza scores phase 3 primary endpoint

Demonstrates efficacy as a preventative treatment

armadillo in chains

Should there be a punishment?

I mean for people who use the word innovation willy-nilly.Is it just us here at P&P, or has the word lost its meaning? Dictionaries define it as a new idea...

Page & Page Health

- PMLiVE

Amgen takes aim at Alexion’s patents for Soliris

Follows extension of Soliris patent protection until 2027

- PMLiVE

AZ’s Farxiga heart failure results wow the ESC

Chases after market leader Jardiance

- PMLiVE

New faces at 90TEN, Lucid Group and Porterhouse

Latest movers in healthcare comms

- PMLiVE

Johnson’s move to shorten Brexit debate faces backlash

Pharma opposed to no-deal, but backs pro-industry plans

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links